Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$17.46 USD
-0.27 (-1.52%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $17.47 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
TEVA 17.46 -0.27(-1.52%)
Will TEVA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TEVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TEVA
TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?
TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up
TEVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Teva Pharmaceutical Industries (TEVA) Reports Q2 Earnings: What Key Metrics Have to Say
Is Teva Pharmaceutical Industries (TEVA) Stock Undervalued Right Now?
Hospital Business Recovery to Aid Haemonetics' (HAE) Q1 Earnings
Other News for TEVA
FTC weighs in on reverse-payment generic delay case involving Gilead, Teva
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
Teva presents new Phase 3 efficacy, safety data from SOLARIS trial
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-`749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY? (risperidone) Extended-Release Injectable Suspension from Perseris? (RBP-7000)